LMTX drug shows promise for use in Parkinson’s disease therapy

Preclinical results from TauRx Therapeutics Ltd (Aberdeen, Scotland) have indicated that LMTM, the active agent in its LMTX® drug originally developed for Alzheimer’s disease (AD) treatment, may also be beneficial as a Parkinson’s disease (PD) medication.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.

alpha-synuclein Alzheimer's disease drug development Parkinson's disease